September, 2015: Plasma Gelsolin Patent Portfolio Further Expands Coverage in Asia - BioAegis Therapeutics

Skip to content

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

September, 2015: Plasma Gelsolin Patent Portfolio Further Expands Coverage in Asia

September 28, 2015

Patents Granted for Renal Failure in Japan and Inflammation in Korea

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – September, 2015) BioAegis Therapeutics announced today patents were recently granted covering plasma gelsolin uses for renal failure in Japan and inflammation in Korea. Further applications in jurisdictions in Asia are also pending.

Stay informed of our latest discoveries and news.

EMAIL

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

February 27, 2024

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

May 12, 2023

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US

Twitter Linkedin Youtube Medium

©2023 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use